MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Leukemia, Hematologic, Blood
Curis, Inc. (NASDAQ: CRIS)*
Organization & Developments: Curis
Parents
Curis, Inc. (NASDAQ: CRIS)*
Children
2011: Curis and Genentech Unleash the Hedgehog to Fight a Deadly Skin Cancer (2011)
2017: Curis Dares To Be Different - Curis, Inc. (NASDAQ:CRIS)
2018: Curis Announces 1-for-5 Reverse Stock Split
2018: Curis Announces Effectiveness of 1-for-5 Reverse Stock Split
2018: Curis Announces FDA Fast Track Designation for Fimepinostat Development in Patients with Relapsed
2018: Curis: Time To Bet On A Courageous Choice - Curis, Inc. (NASDAQ:CRIS)
2018: Why I Sold Curis Inc (NASDAQ:CRIS) – Simply Wall St News
2019: Curis: Speculative Targeted Oncology Story With 3 Readouts In 2019 - Curis, Inc. (NASDAQ:CRIS)
2020: Curis stock more than triples on massive volume after upbeat leukemia treatment trial results
2021: Curis: Differentiated IRAK4 Inhibitor To Drive Value Creation In The Near Term
2022: Curis gets FDA green light to restart lymphoma trial, though partial hold on leukemia study stays in place
2022: Curis Is A Speculative Play That Could Produce Solid Returns_
2022: Curis shrinks headcount by 30% as execs place bigger hopes on blood cancer drug
2022: Patient death triggers a second clinical hold for Curis as FDA seeks more data
Jumps
*Key People: Curis
Finance & Acquisitions: Curis